Department of Medical Oncology, St Vincent's Hospital, Melbourne, Australia.
Department of Medical Oncology, St Vincent's Hospital, Melbourne, Australia.
J Clin Neurosci. 2019 Oct;68:1-8. doi: 10.1016/j.jocn.2019.08.017. Epub 2019 Aug 12.
Molecular aberrations of malignancy are becoming widely recognized as important predictive and prognostic markers for treatment response and survival in oncology and have been linked to the discovery of novel treatment targets. This area of research in glioblastoma continues to evolve. The aim of this scoping review was to document the hallmark molecular characteristics of long-term survivors of glioblastoma. MEDLINE, Scopus and EMBASE were searched with core concepts: (1) glioblastoma, (2) long-term survivor and (3) molecular OR mutation. A thematic analysis was undertaken of the 18 included studies. Four main classes of characteristics were obtained: IDH mutation, MGMT methylation, other known characteristics and novel discoveries. While MGMT methylation or the combination with IDH mutation are suggested to be hallmark characteristics, there remains enough uncertainty to suggest further factors may be involved, such as CD34 expression. Further research is required to accurately describe hallmark molecular characteristics of long-term survivors to assist in defining these patients at diagnosis, preventing treatment complications and discovering novel treatments.
恶性肿瘤的分子异常正逐渐被广泛认为是肿瘤学中治疗反应和生存的重要预测和预后标志物,并与新的治疗靶点的发现有关。胶质母细胞瘤的这一研究领域仍在不断发展。本范围综述的目的是记录胶质母细胞瘤长期幸存者的标志性分子特征。通过核心概念搜索了 MEDLINE、Scopus 和 EMBASE:(1)胶质母细胞瘤,(2)长期幸存者,(3)分子或突变。对纳入的 18 项研究进行了主题分析。获得了四个主要特征类别:IDH 突变、MGMT 甲基化、其他已知特征和新发现。虽然 MGMT 甲基化或与 IDH 突变的组合被认为是标志性特征,但仍存在足够的不确定性,表明可能涉及其他因素,如 CD34 表达。需要进一步研究以准确描述长期幸存者的标志性分子特征,以帮助在诊断时确定这些患者,预防治疗并发症和发现新的治疗方法。